Multiple Myeloma | Disease Landscape and Forecast | G7 | 2018

Market Outlook

Celgene’s Revlimid and Janssen/Takeda Pharmaceutical’s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant commercial reward for some well-entrenched current therapies. Emerging agents such as AbbVie/Roche/Genentech’s Venclexta/Venclyxto, Karyopharm Therapeutics’ selinexor, Sanofi/ImmunoGen’s isatuximab, and Bluebird Bio/Celgene’s bb2121 are pursuing initial approvals for the treatment of multiple myeloma, highlighting that untapped clinical and commercial potential exists in multiple myeloma for therapies with improved efficacy, novel mechanisms of action, and positioned in patient segments that are currently underserved.

Questions Answered

  • Revlimid and Velcade are widely used for the current treatment of multiple myeloma, but how will the use of these agents change over the forecast period? What impact will generic entries of these pivotal agents have on the multiple myeloma market?
  • How has the approval of Janssen’s Darzalex and Bristol-Myers Squibb/AbbVie’s Empliciti impacted the multiple myeloma market? How important will these agents become over the forecast period?
  • What are thought-leaders’ opinions on agents in Phase III development, such as Merck & Co.’s Keytruda, Bristol-Myers Squibb/Ono Pharmaceutical’s Opdivo, Sanofi/ImmunoGen’s isatuximab, Bluebird Bio/Celgene’s bb2121, and GlaxoSmithKline’s GSK2857916? What impact will these agents have on the multiple myeloma market?
  • What are the drivers and constraints in the multiple myeloma market, and how will the market evolve over the forecast period?

Product Description

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.